| Excerpt | Reference |
|---|
| "Secondary hyperparathyroidism is common in dialysis patients." | ( Felsenfeld, AJ; Llach, F; Pederson, JA; Rodriguez, M; Williams, C, 1991) |
| "Secondary hyperparathyroidism is commonly observed in dialysic patients." | ( Llach, F; Nikakhtar, B, 1991) |
| "Further secondary hyperparathyroidism is ameliorated by nisoldipine treatment." | ( Hirth-Dietrich, C; Kazda, S; Neuser, D; Stasch, JP, 1990) |
| "Secondary hyperparathyroidism is suggested to be responsible, at least partly, for sexual dysfunction in male patients on maintenance hemodialysis." | ( Bogićević, M; Stefanović, V, 1988) |
| "In this patient secondary hyperparathyroidism is thought to be due to 1,25(OH)2D deficiency, and the decreased responsiveness to exogenous PTH before treatment due to excess PTH occupying renal receptors." | ( Fujita, T; Fukase, M; Ishida, M; Ishii, T; Seino, Y; Shimotsuji, T; Yabuuchi, H; Yamaoka, K, 1981) |
| "Severe secondary hyperparathyroidism is still observed at present in 5-10% of haemodialysis patients." | ( Bourdeau, A; Bourdon, R; Cournot-Witmer, G; Dubost, C; Jorgetti, V; Lavergne, A; Lecharpentier, Y; Mendes, V; Nemeth, J; Zingraff, J, 1984) |
| "This senile secondary hyperparathyroidism is one of the determinants of femoral bone loss and can be reversed by calcium and vitamin D supplements." | ( Arlot, ME; Chapuy, MC; Delmas, PD; Duboeuf, F; Meunier, PJ, 1994) |
| "Secondary hyperparathyroidism is one of the severe complications of chronic renal failure." | ( Fujisaki, T; Hida, M; Hiraga, S; Osamura, RY, 1997) |
| "Secondary hyperparathyroidism is a common feature of chronic renal failure and vitamin D deficiency plays an important role in the development of this abnormality." | ( Andreini, B; De Pietro, S; Ferdeghini, M; Giovannini, L; Migliori, M; Palla, R; Panichi, V; Taccola, D, 1998) |
| "The etiology of secondary hyperparathyroidism is multifactorial, and as many as 10% of patients will ultimately require surgical intervention." | ( Gordon, HE; Hines, OJ, 1998) |
| "2) Secondary hyperparathyroidism is most frequently seen in patients who have undergone intestinal resection(s)." | ( Andreassen, H; Brot, C; Eskildsen, P; Rix, M, 1998) |
| "Secondary hyperparathyroidism is a universal complication in patients with chronic renal failure." | ( Brown, A; Dusso, A; Slatopolsky, E, 1999) |
| "Secondary hyperparathyroidism is a frequent complication of chronic renal failure (CRF) and a major factor in the pathogenesis of renal osteodystrophy." | ( Kilav, R; Naveh-Many, T; Sela-Brown, A; Silver, J, 2000) |
| "Secondary hyperparathyroidism is the most common skeletal lesion in pediatric patients undergoing maintenance dialysis." | ( Goodman, WG; Kuizon, BD; Salusky, IB, 2000) |
| "Secondary hyperparathyroidism is the most common form of this condition found in renal osteodystrophy." | ( Ambrosoni, P; Caorsi, H; Caputti, S; Di Trápani, N; Heuguerot, C; López, J; Olaizola, I; Parodi, MN; Petraglia, A, 2000) |
| "Secondary hyperparathyroidism is a frequent condition of dialysis patients." | ( Carpinteri, G; Catalano, D; Iannetti, E; Squatrito, R; Trovato, GM; Vitale, M, 2000) |
| "Secondary hyperparathyroidism is a well known complication of chronic renal insufficency." | ( Brzac, HT; Pavlović, D, 2003) |
| "Secondary hyperparathyroidism is a common complication of renal failure." | ( Elhwairis, H; Narra, S; Osama, S; Owda, A; Towery, H, 2003) |
| "Secondary hyperparathyroidism is often complicated by elevations in calcium and phosphorus either as a result of the disease per se or due to toxicity from current therapeutic options." | ( Block, GA, 2003) |
| "Secondary hyperparathyroidism is a major complication in uremic patients undergoing dialysis." | ( Ishiguro, N; Iwanaga, Y; Kubota, M, 2003) |
| "Management of secondary hyperparathyroidism is challenging with traditional therapy." | ( Albizem, MB; Borah, MF; Clark, RV; Coburn, JW; Culleton, B; Guo, MD; Husserl, FE; Klassen, PS; Lindberg, JS; Roger, SD; Shapiro, WB; Wong, G, 2005) |
| "Secondary hyperparathyroidism is associated with progressive bone loss." | ( Lien, YH; Silva, AL; Whittman, D, 2005) |
| "Adrenal secondary hyperparathyroidism is a cause of increased PTH concentrations and may be associated with abnormalities in calcium and phosphate metabolism in dogs with HAC." | ( Evans, H; Harris, E; Herrtage, ME; Ramsey, IK; Tebb, A, 2005) |
| "Secondary hyperparathyroidism is sometimes seen in patients with hypophosphatemic osteomalacia after long-term oral phosphate therapy." | ( Chang, YC; Liao, KM; Su, DH; Tsai, KS, 2006) |
| "Secondary hyperparathyroidism is a common complication of patients with chronic kidney disease." | ( Cheng, S; Coyne, D, 2006) |
| "The main cause of secondary hyperparathyroidism is active vitamin D deficiency." | ( Benner, D; Kalantar-Zadeh, K; Lee, GH; Regidor, DL, 2007) |
| "Secondary hyperparathyroidism is highly prevalent in patients with end-stage renal disease." | ( Amin, H; Cooke, CR; Wall, BM, 2007) |
| "Secondary hyperparathyroidism is a common complication of chronic kidney disease, resulting from inactivation of vitamin D receptor signaling and phosphate retention." | ( Abboud, H; Hamm, LL; Hippensteel, R; Melnick, JZ; Pradhan, RS; Ross, EA; Sprague, SM; Tian, J; Williams, LA, 2008) |
| "Secondary hyperparathyroidism is an important factor in the pathogenesis of cardiovascular complications in CKD." | ( Garg, D; Nair, M; Sahni, V; Singh, NP, 2007) |
| "We conclude that secondary hyperparathyroidism is prevalent in our dialysis population and has high correlation with serum alkaline phosphatase levels and radiological changes." | ( Behzad, F; Rahimian, M; Sami, R, 2008) |
| "Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease and treatment with vitamin D analogues is a mainstay of therapy." | ( Martin, JE; Moe, S; Wazny, LD, 2008) |
| "Management of secondary hyperparathyroidism is difficult because of the interrelationship of parathyroid hormone, calcium and phosphorus." | ( Al-Azmi, M; Al-Helal, B; Al-Hilali, N; Al-Humoud, H; Al-Kandari, NH; Johny, KV, 2008) |
| "The management of secondary hyperparathyroidism is made more complex by the fact that the disease progresses over time." | ( Limardo, M; Locatelli, F; Pontoriero, G, 2008) |
| "Treating secondary hyperparathyroidism is challenging, as most of the parameters of mineral metabolism are interconnected." | ( Bonny, O; Burnier, M, 2008) |
| "Secondary hyperparathyroidism is also related to increased cardiovascular mortality in CKD patients." | ( Floege, J; Schlieper, G, 2008) |
| "Secondary hyperparathyroidism is observed in patients with early chronic kidney disease (CKD)." | ( Abboud, HE; Albizem, MB; Block, GA; Charytan, C; Chonchol, M; de Francisco, AL; Jolly, S; Kaplan, M; Kubo, Y; Locatelli, F; Mix, TC; Roger, SD; Sarkar, S, 2009) |
| "Secondary hyperparathyroidism is characterized by increased parathyroid hormone (PTH) mRNA stability that leads to increased PTH mRNA and serum PTH levels." | ( Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J, 2009) |
| "Secondary hyperparathyroidism is common in patients with CKD, and its relationship to CVD is not well defined." | ( Bakris, GL; Bhuriya, R; Chen, SC; Li, S; McCullough, PA, 2009) |
| "Secondary hyperparathyroidism is a common complication in uremic patients." | ( Conti-Freitas, LC; da Costa, JA; Foss, MC; Foss-Freitas, MC; Lucca, LJ; Mamede, RC, 2009) |
| "Secondary hyperparathyroidism is one of the most popular complications in patients with chronic kidney disease." | ( Fukagawa, M; Goto, S, 2009) |
| "Secondary hyperparathyroidism is a serious complication of chronic renal disease when function decline and is characterized by abnormalities in serum calcium and phosphate profile, along with a decline in calcitriol synthesis." | ( Brancaccio, D; Cozzolino, M; Fallabrino, G; Gallieni, M; Olivi, L; Pasho, S, 2009) |
| "Secondary hyperparathyroidism is common among dialysis patients and leads to numerous complications including cardiovascular disease and renal osteodystrophy." | ( Coyne, DW; Gincherman, Y; McKee, C; Moloney, K, 2010) |
| "Renal secondary hyperparathyroidism is a complex, multifactorial syndrome that involves changes in circulating levels of calcium, PTH, phosphorus, and 1,25-dihydroxycholecalciferol (calcitriol)." | ( Ritt, MG; Stillion, JR, 2009) |
| "Secondary hyperparathyroidism is a major complication of chronic kidney disease (CKD)." | ( Mor Yosef-Levi, I; Naveh-Many, T; Nechama, M; Silver, J; Uchida, T, 2009) |
| "Secondary hyperparathyroidism is a common feature in patients with chronic kidney disease." | ( Brandi, L; Hansen, D; Rasmussen, K, 2009) |
| "Secondary hyperparathyroidism is common in chronic kidney disease." | ( Chan, HW; Cheuk, A; Chu, KH; Fung, SK; Lee, KC; Lee, W; Tang, HL; Tong, MK; Yim, KF, 2010) |
| "Secondary hyperparathyroidism is associated with an increased risk of skeletal fractures and mortality in dialysis patients." | ( Torres, PU, 2011) |
| "Secondary hyperparathyroidism is a common complication of chronic kidney disease (CKD) that is associated with bone disease, cardiovascular disease and death." | ( Anderson, AH; Anderson, CA; Bellovich, K; Feldman, HI; Gutiérrez, OM; He, J; Isakova, T; Leonard, MB; Rosen, LK; Steigerwalt, SP; Tang, I; Theurer, J; Townsend, RR; Wolf, M; Xie, D, 2011) |
| "Secondary hyperparathyroidism is a characteristic feature of chronic kidney disease, which develops early in the course of chronic kidney disease, often in a progressive way." | ( Al-Baaj, F; Al-Rifai, A; Yadav, P, 2011) |
| "Secondary hyperparathyroidism is a potentially detrimental condition, especially in patients already suffering from another bone disease." | ( Anastasilakis, AD; Makras, P; Polyzos, SA; Terpos, E, 2011) |
| "Secondary hyperparathyroidism is a common manifestation of chronic kidney disease (CKD)." | ( Gadde, S; Greenberg, M; Greenberg, S; Janga, K; Pagala, M; Shneyderman, I, 2011) |
| "Severe secondary hyperparathyroidism is a complication of chronic kidney disease." | ( Cigarrán, S; Coronel, F; Gomis, A; Rodríguez-Cubillo, B, 2011) |
| "Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease." | ( Cerezo Morales, S; Hervás Sánchez, JG; Polo Moyano, A; Prados Garrido, MD, 2011) |
| "Secondary hyperparathyroidism is a common complication of chronic kidney disease and it is associated with high morbidity and mortality." | ( Karohl, C; Raggi, P, 2012) |
| "Secondary hyperparathyroidism is frequent in prostate cancer patients with bone metastases, and this condition is worsened by the administration of potent bisphosphonates." | ( Berruti, A; Buttigliero, C; Coleman, RE; Cook, R; Lee, KA; Lipton, A; Saad, F; Smith, MR; Tampellini, M, 2012) |
| "Secondary hyperparathyroidism is a relevant problem in patients on dialysis." | ( Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Soler, M; Torregrosa, JV, 2012) |
| "Secondary hyperparathyroidism is the most common abnormalities of mineral metabolism in chronic kidney disease (CKD), which causes bone disease and vascular calcification, leading to increased risk of mortality." | ( Fukagawa, M; Kakuta, T; Komaba, H, 2013) |
| "Secondary hyperparathyroidism is a common complication in patients with chronic kidney disease and frequently persists after kidney transplantation." | ( Bayés, B; Bonet, J; Cañas, L; Lauzurica, R; Navarro-Muñoz, M; Pastor, MC; Pérez, V; Romero, R; Sánchez-Escuredo, A, 2013) |
| "Secondary hyperparathyroidism is not involved in postoperative bone loss." | ( Abegg, K; Bueter, M; Gehring, N; Liesegang, A; Lutz, TA; Schiesser, M; Wagner, CA, 2013) |
| "Secondary hyperparathyroidism is an almost inevitable complication of advanced kidney failure." | ( du Buf-Vereijken, PW; Manamley, N; Potter van Loon, BJ; Reichert, LJ; Smak Gregoor, PJ; Vervloet, MG, 2013) |
| "Secondary hyperparathyroidism is highly prevalent after bariatric surgery." | ( Alexandrou, A; Armeni, E; Augoulea, A; Creatsa, M; Deligeoroglou, E; Diamantis, T; Kaparos, G; Lambrinoudaki, I; Rizos, D; Tsoka, E, 2015) |
| "Secondary hyperparathyroidism is a frequent complication of chronic kidney disease." | ( Rodríguez, M; Rodríguez-Ortiz, ME, 2015) |
| "Secondary hyperparathyroidism is highly prevalent in kidney transplant recipients, and commonly results in hypercalcaemia; an association to osteopenia and bone fractures has also been observed." | ( Acosta Martínez, Y; Borrego Utiel, FJ; Bravo Soto, JA; García Álvarez, T; González Carmelo, I; López Jiménez, V; Mazuecos Blanca, MA; Merino Pérez, MJ, 2015) |
| "Secondary hyperparathyroidism is one such complications that leads to increased parathyroid hormone levels due to a decrease in calcium and vitamin D, which may compromise bone health." | ( Baretta, GA; Cambi, MP; Mendes, SA; Rodrigues, AL, 2015) |
| "Secondary hyperparathyroidism is almost a constant feature in chronic kidney disease (CKD) patients maintained on hemodialysis (HD)." | ( Aamer, MA; Bashir, SO; Morsy, MD; Omer, HA; Somialy, R, 2015) |
| "Secondary hyperparathyroidism is a common complication in chronic renal failure." | ( Alhamany, Z; Bayahia, R; Belkouchi, M; Benamar, L; El Malki, H; Elouazzani, H; Mattous, M; Ouzeddoun, N; Skalli, Z, 2015) |
| "Secondary hyperparathyroidism is common among patients with ESRD." | ( Chertow, GM; Kim, SM; Leonard, MB; Long, J; Montez-Rath, ME; Norton, JA, 2016) |
| "Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach." | ( Bock, A; Hemetsberger, M; Jäger, C; Klauser-Braun, R; Lhotta, K; Pendl, G; Pronai, W; Rosenkranz, AR, 2017) |
| "Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet." | ( Adragão, T; Barata, JD; Branco, P; Conde, SQ; Gaspar, A; Sousa, H, 2017) |
| "Persistent secondary hyperparathyroidism is common after successful kidney transplant, with concomitant hypercalcemia and hypophosphatemia potentially leading to reduced graft survival and increased cardiovascular risk." | ( Fyssa, L; Goumenos, DS; Ntrinias, T; Papachristou, E; Papasotiriou, M; Savvidaki, E; Zavvos, V, 2018) |
| "Secondary hyperparathyroidism is characterized by parathyroid gland (PG) hyperplasia, and excessive synthesis and secretion of parathyroid hormone (PTH)." | ( Chen, J; Kan, S; Mao, J; Ni, L; Wang, M; Zhang, M; Zhang, Q; Zhang, W, 2018) |
| "Secondary hyperparathyroidism is a complication of chronic kidney disease that compromises skeletal integrity." | ( Carvalho, AB; Dominguez, WV; Dos Reis, LM; Hernandes, FR; Jorgetti, V; Montenegro, FM; Moysés, RM; Oliveira, IB; Pires, GO; Teixeira, AL; Vieira, IO, 2019) |
| "Secondary hyperparathyroidism is a frequent complication of chronic kidney disease that begins early in the course of renal insufficiency as an adaptive response to maintain mineral homeostasis." | ( Bellorin-Font, E; Martin, KJ; Vasquez-Rios, G, 2019) |
| "Secondary hyperparathyroidism is part of the complex of chronic kidney disease-associated mineral and bone disorders (CKD-MBD) and is linked with high bone turnover, ectopic calcification, and increased cardiovascular mortality." | ( Haffner, D; Leifheit-Nestler, M, 2020) |
| "Secondary hyperparathyroidism is a complex pathology that develops as chronic kidney disease progresses." | ( Rodríguez, M; Rodríguez-Ortiz, ME, 2020) |
| "Features of secondary hyperparathyroidism are common in the postpartum." | ( Badillo-Pazmay, GV; Catena, C; Cogo, PE; Colussi, G; Darsiè, D; Driul, L; Fagotto, V; Pezzutto, F; Romano, G; Sechi, LA, 2021) |
| "Secondary hyperparathyroidism is caused by alterations in calcium, phosphate, and vitamin D regulation that result in elevated parathyroid hormone levels." | ( Partin, M; Ramirez, S; Sell, J, 2022) |
| "Secondary hyperparathyroidism is a major complication of patients undergoing hemodialysis (HD)." | ( Akizawa, T; Fukagawa, M; Hagita, K; Honda, D; Isaka, Y; Koiwa, F; Shigematsu, T; Watanabe, YS, 2023) |
| Excerpt | Reference |
|---|
| "We reported a successful treatment of secondary hyperparathyroidism by intermittent oral administration of high dose of 1, 25 dihydroxycholecalciferol [1." | ( Kawaguchi, Y; Miyahara, T; Momose, M; Morita, T; Nakayama, M; Ogawa, A; Shigematsu, T; Suzuki, M; Unemura, S; Yamamoto, H, 1989) |
| "This treatment may help to prevent or treat secondary hyperparathyroidism in patients receiving long-term dialysis." | ( Hasegawa, T; Ikeda, M; Kawaguchi, Y; Momose, M; Sakai, O; Shigematsu, T; Unemura, S; Wakabayashi, Y; Yamamoto, H; Yokoyama, K, 1993) |
| "Recent approaches to prevent and treat secondary hyperparathyroidism in dialysis patients include decreasing dialysate Ca content from 1." | ( Argilés, A; Mion, CM, 1995) |
| "Calcitriol, as used for treating secondary hyperparathyroidism, has a low therapeutic index." | ( Bishop, CW; Coburn, JW; Kleinman, KS; Knutson, JC; Kyllo, DM; Levine, BS; Mazess, RB; Tan, AU, 1997) |
| "calcitriol over a 1-year period in the treatment of severe secondary hyperparathyroidism (HPT), in particular its effect on bone mineral density (BMD) and parathyroid gland mass." | ( Abed, J; Abu-Aisha, H; Al Desouki, M; Al Wakeel, J; Huraib, S; Memon, N, 1997) |
| "The prevention and treatment of the secondary hyperparathyroidism of chronic renal failure by medical means relies on a number of different possible approaches, which should be tailored to each patient's individual needs." | ( Drüeke, TB, 1999) |
| "Bolus calcitriol (CTR) is used for the treatment of secondary hyperparathyroidism in dialysis patients." | ( Betriu, A; Borrego, MJ; Caravaca, F; Cubero, J; Felsenfeld, AJ; Fernandez, E; Jimenez, A; Lorenzo, V; Martin-Malo, A; Rodriguez, M; Torres, A, 1999) |
| "Effective treatment of secondary hyperparathyroidism (HPTH) with intravenous (i." | ( Balaskas, E; Benos, A; Grekas, D; Kampouris, H; Konstantinou, A; Sioullis, A; Tourkantonis, A, 1999) |
| "Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients." | ( Indridason, OS; Quarles, LD, 2000) |
| "Paricalcitol was evaluated for the treatment of secondary hyperparathyroidism (SHPT) in a long-term, prospective, open-label study of 37 patients with end-stage renal failure resistant to intravenous calcitriol." | ( Llach, F; Yudd, M, 2001) |
| "Immunosuppresive treatment and secondary hyperparathyroidism (SHPT) are considered among the most important pathogenetic factors for postrenal transplant bone disease." | ( Carraro, G; Crepaldi, G; D'Angelo, A; Dalle Carbonare, L; Giannini, S; Marchini, F; Nobile, M; Pavan, S; Rigotti, P; Sartori, L; Silva-Netto, F; Zaninotto, M, 2002) |
| "Current treatment of secondary hyperparathyroidism in chronic kidney failure with calcium and active vitamin D is potentially limited by hypercalcemia and hyperphosphatemia." | ( Adler, S; Bushinsky, DA; Liu, W; McCary, LC; Quarles, LD; Rosansky, SJ; Sherrard, DJ; Turner, SA, 2003) |
| "Calcimimetic agents thus offer a novel treatment for secondary hyperparathyroidism in patients with chronic kidney disease stage 5, who are managed with dialysis." | ( Goodman, WG, 2004) |
| "Prevention and treatment of secondary hyperparathyroidism (SHPT) in patients on chronic maintenance hemodialysis and of tertiary hyperparathyroidism (THPT) in patients after kidney transplantation is a challenge for the nephrologist and for the surgeon." | ( Rothmund, M; Schlosser, K; Zielke, A, 2004) |
| "Calcitriol treatment of secondary hyperparathyroidism (HPT) in chronic kidney disease (CKD) patients can lead to increased serum calcium and phosphorus, which have been associated as risk factors for vascular calcification." | ( Cattley, RC; Colloton, M; Henley, C; Lacey, D; Martin, D; Shatzen, E; Towler, DA, 2005) |
| "We concern about vitamin D, one of the treatment for secondary hyperparathyroidism has some adverse effects on the kidney function." | ( Inaba, S; Inaguma, D; Kato, T; Mishima, T; Nakamura, T; Shinjo, H; Suzuki, S; Tatematsu, M, 2005) |
| "For the treatment of secondary hyperparathyroidism (HPTH-II) in dialysis patients and hypercalcemia in patients with parathyroid carcinoma." | ( Abbassi, A; Chuong, VT; de Vernejoul, MC; Guédon, C; Roueff, S; Saint Georges, M; Ureña Torres, P, 2006) |
| "Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium." | ( Fukagawa, M; Nakanishi, S, 2007) |
| "Medical treatment for secondary hyperparathyroidism (HPTH-II) consists in correcting: hypocalcemia by providing a supply of calcium salts, vitamin D or its derivatives; hyperphosphatemia by a suitable diet and by using gastrointestinal phosphate-binders; metabolic acidosis by providing sodium bicarbonate." | ( Canaud, B; Torres, PU, 2005) |
| "Calcitriol is used for the treatment of secondary hyperparathyroidism." | ( Brown, AJ; Clagett-Dame, M; DeLuca, HF; Finch, JL; Mizobuchi, M; Plum, LA; Ritter, CS; Sicinski, RR; Slatopolsky, E, 2007) |
| "The ""classical"" treatment of secondary hyperparathyroidism and hyperphosphatemia in ESRD patients consists of either calcium- or aluminum-based phosphate binders and calcitriol administration." | ( Brancaccio, D; Cozzolino, M, 2007) |
| "Calcimimetics for the treatment of secondary hyperparathyroidism were administered in about 10% of patients." | ( Alisauskiene, V; Burciuviene, A; Grazulis, S; Juodeikiene, L; Kuzminskis, V; Masalskiene, J; Petrauskiene, V; Sileikiene, E; Tamosaitis, D; Ziginskiene, E, 2007) |
| "The traditional treatment of secondary hyperparathyroidism, which affects many patients with chronic kidney disease and is associated with an increased risk of morbidity and mortality, is not very effective." | ( Limardo, M; Locatelli, F; Pontoriero, G, 2007) |
| "Drug treatment for secondary hyperparathyroidism caused by chronic renal failure may be available at the early stage of the disease, but it is not as effective for serious patients." | ( Gu, Y; Jin, YT; Lao, ZY; Li, HM; Li, MX; Wang, HY; Xue, J; Zhang, YL; Zhou, J; Zou, Q, 2007) |
| "Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium." | ( Fukagawa, M; Nakanishi, S, 2008) |
| "The "classical" treatment of secondary hyperparathyroidism and hyperphosphatemia in CKD patients consists of either calcium or aluminium based phosphate-binders and calcitriol administration." | ( Brancaccio, D; Cozzolino, M, 2007) |
| "Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis." | ( Cannata-Andía, JB; Fernández-Martín, JL, 2009) |
| "Cinacalcet is an effective treatment for secondary hyperparathyroidism (SHPT) in patients with uremia on hemodialysis." | ( Imanishi, Y; Inaba, M; Kawata, T; Nishizawa, Y, 2009) |
| "The optimal treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) is unknown." | ( LaClair, RE; Moe, SM; Saifullah, A; Usman, SA; Yu, Z, 2010) |
| "Cinacalcet is used for treating secondary hyperparathyroidism in dialysis patients, but it is currently unknown whether it can safely be continued immediately after renal transplantation." | ( Aalten, J; Hoitsma, AJ; Wetzels, JF, 2010) |
| "Cinacalcet treatment for secondary hyperparathyroidism (SHPT) has demonstrated parathyroid size regression and morphological changes, such as cystic degeneration and hypovascularisation, on ultrasonography." | ( Inoshita, N; Marui, Y; Nakamura, M; Ohashi, K; Sumida, K; Takaichi, K; Tanaka, K; Tomikawa, S; Ubara, Y, 2011) |
| "We explored the changes in FGF23 during treatment of secondary hyperparathyroidism (SHPT) with alfacalcidol or paricalcitol in haemodialysis patients." | ( Brandi, L; Hansen, D; Pedersen, SM; Rasmussen, K; Rasmussen, LM, 2012) |
| "Vitamin D analogs are used for treatment of secondary hyperparathyroidism in patients with chronic kidney disease in order to prevent renal osteodystrophy, bone fracture and pain." | ( Hansen, D, 2012) |
| "Optimal treatment for secondary hyperparathyroidism (SHPT) has not been defined." | ( Amdahl, M; Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Marx, S; Sharma, A; Wolf, M, 2012) |
| "In the surgical treatment of secondary hyperparathyroidism (2HPT) of chronic kidney disease (CKD), a parathyroidectomy (PTx) of 4 glands can only be presumed as 'total', and indications for autoimplantation are complex." | ( Avenia, N; Conzo, G; De Santo, RM; Della Pietra, C; Palazzo, A; Perna, A; Santini, L; Sinisi, AA; Stanzione, F, 2012) |
| "Cinacalcet is effective for treating refractory secondary hyperparathyroidism (SHPT), but little is known about the response rates and clinical factors influencing the response." | ( Choi, KB; Choi, KH; Hwang, SD; Kim, JK; Kim, SW; Kim, YH; Kwon, YJ; Park, CW, 2013) |
| "Cinacalcet is a new effective treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients (HP), but the alterations of parathyroid gland (PTG) hyperplasia determined by cinacalcet and vitamin D have not been extensively investigated in humans." | ( Bossola, M; Di Stasio, E; Fadda, G; Silvestri, P; Tazza, L; Vulpio, C, 2013) |
| "Calcitriol is used to treat secondary hyperparathyroidism in patients with CKD." | ( Coyne, DW; Faber, M; Ghossein, C; Goldberg, S; Sprague, SM, 2014) |
| "Cinacalcet is one of the important treatments of secondary hyperparathyroidism (SHPT)." | ( Cho, YS; Hong, YA; Hwang, SY; Jung, MY; Kim, SW; Ko, GJ; Kwon, YJ; Lee, EA; Pyo, HJ; Suh, S, 2015) |
| "Cinacalcet is indicated for treatment of secondary hyperparathyroidism in patients receiving hemodialysis." | ( Bradbury, BD; Brunelli, SM; Cooper, K; Dluzniewski, PJ; Do, TP; Sibbel, S, 2015) |
| "Cinacalcet is used to treat secondary hyperparathyroidism among hemodialysis patients." | ( Bradbury, BD; Brookhart, MA; Dluzniewski, PJ; Do, TP; Kshirsagar, AV; Reams, BD; Yue, SV, 2015) |
| "Microwave ablation (MWA) can be used to treat severe secondary hyperparathyroidism; however, its efficacy and the predictor of its efficacy are unclear." | ( Diao, Z; Liu, J; Liu, S; Liu, W; Liu, X; Qian, L, 2016) |
| "The calcimimetic cinacalcet is used to treat secondary hyperparathyroidism in patients receiving dialysis, and asymptomatic hypocalcemia is often observed following its initiation." | ( Chertow, GM; Drueke, TB; Floege, J; Iles, J; Parfrey, P; Tsirtsonis, K, 2018) |
| "Overall, compared with calcitriol treatment for secondary hyperparathyroidism in dialysis patients, paricalcitol treatment has comparable ≥50% reduction of parathyroid hormone (risk ratio [RR] = 1." | ( Chen, H; Ju, H; Wen, W; Zhang, T, 2019) |
| "The CaSR is a therapeutic target in the treatment of secondary hyperparathyroidism and hypocalcemia a common complication of calcimimetic therapy." | ( Alexander, RT; Beggs, MR; Chen, XZ; Dimke, H; Flockerzi, V; Lee, JJ; Liu, X; O'Neill, D; Weissgerber, P, 2019) |
| "Parathyroidectomy (PTX) is the standard treatment for secondary hyperparathyroidism (SHPT); however, the administration of cinacalcet has gained prominence as a noninvasive treatment." | ( Chung, WY; Jeong, JJ; Kang, SW; Kim, BS; Kim, K; Kim, WW; Lee, CR; Lee, J; Nam, KH; Rhee, Y, 2019) |
| "Recommendations for the treatment of secondary hyperparathyroidism (sHPT) and preservation of bone health in pregnant dialysis patients are lacking." | ( Cejna, M; Kronbichler, A; Lhotta, K; Sprenger-Mähr, H; Zitt, E, 2019) |
| "Calcimimetic treatment of secondary hyperparathyroidism in chronic dialysis patients is often followed by hypocalcemia." | ( Erhard, C; Floege, J; Fouqueray, B; Louie, KS; Stenvinkel, P; Wheeler, DC, 2020) |
| "The data on the treatment of secondary hyperparathyroidism (SHPT) provided in scientific publications are divergent and contradictory." | ( Idasiak-Piechocka, I; Lacka, K; Miedziaszczyk, M; Wiśniewski, OW, 2022) |
| "Medical treatment of secondary hyperparathyroidism has considerably evolved over the past 2 decades, with parathyroidectomy reserved for severe cases." | ( Ahn, JB; Mathur, A; McAdams-DeMarco, M; Segev, DL; Sutton, W; Zeiger, MA, 2022) |